# A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

> **NCT06372145** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 2500 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Progressive Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Tolebrutinib
- **DRUG:** Placebo
- **DRUG:** Teriflunomide

## Key facts

- **NCT ID:** NCT06372145
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 2500 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06372145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06372145, "A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06372145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*